ENDRA Life Sciences Inc

NAS:NDRAHealthcarenasdaq_composite

——At close · Market cap — · Next earnings Fri 13 Nov

NDRA · Income statement · TradingHolo

USD millions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM	YoY
Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	—
Cost of revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.2	—
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	(0.2)	—
Research & development	5.9	5.5	6.6	5.0	3.2	1.8	2.0	+5.4%
Selling, general & administrative	5.6	6.0	6.6	5.5	7.6	3.9	—	—
Selling & marketing	0.6	1.1	1.4	0.8	0.6	0.2	—	—
Operating expenses	11.5	11.5	13.2	10.5	10.8	5.8	6.6	+14.7%
Operating income	(11.5)	(11.5)	(13.2)	(10.5)	(10.8)	(5.8)	(6.6)	−15.4%
Interest expense	0.2	0.0	0.0	0.0	0.0	0.0	0.0	—
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Other income / expense	(0.2)	0.3	(0.0)	0.5	(0.7)	(1.3)	—	—
Pre-tax income	(11.7)	(11.2)	(13.2)	(10.1)	(11.5)	(7.0)	(5.9)	+15.8%
Income tax	0.0	0.0	0.0	0.0	0.0	0.0	0.0	—
Net income	(11.7)	(11.2)	(13.2)	(10.1)	(11.5)	(7.0)	(5.9)	+15.8%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—	—
EPS, basic (per share)	(12.47)	(5.47)	(4.57)	(5.89)	(10.25)	(8.93)	(6.32)	+29.2%
EPS, diluted (per share)	(12.47)	(5.47)	(6.84)	(5.89)	(10.25)	(8.93)	(6.38)	+28.6%
EBITDA	(11.3)	(11.0)	(12.9)	(9.8)	(11.3)	(6.9)	(5.7)	+16.8%
Depreciation & amortization	0.2	0.2	0.2	0.3	0.2	0.2	0.1	−56.3%
Weighted average shares (shares)	959,611	2,046,135	1,930,336	1,707,960	1,122,434	787,020	—	—
Weighted average diluted shares (shares)	959,611	2,046,135	1,930,336	1,707,960	1,122,434	787,020	—	—

USD millionsUpdated Fri 2 Oct ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.

TTM ends 2026-06-30 and uses four consecutive reported quarters.